South & Central America CRISPR and Cas Gene Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The South and Central America CRISPR and Cas Gene Market size is expected to reach US$ 622.6 Million by 2031 from US$ 154.4 Million in 2024. The market is estimated to record a CAGR of 22.1% from 2025 to 2031.

Executive Summary and South and Central America CRISPR and Cas Gene Market Analysis:

The South & Central America CRISPR and Cas gene market is segmented into Brazil, Argentina, and the Rest of South & Central America. Governments and private institutions are strengthening genomic research infrastructure, enabling more academic-industry collaborations. The region faces a high burden of genetic and infectious diseases, driving demand for therapeutic approaches and diagnostic tools based on CRISPR. Growing awareness, supportive regulatory developments, and partnerships with global biotech firms accelerate technology transfer and commercialization. Lower costs of CRISPR tools and increasing availability of skilled researchers contribute to market expansion.

South & Central America CRISPR and Cas Gene Market: Strategic Insights

South and Central America CRISPR and Cas Gene Market Segmentation Analysis:

• By Product and Service, the South and Central America CRISPR and Cas Gene Market is segmented into Product and Services. The Product segment dominated the market in 2024.
• By Product For Product and Service, the South and Central America CRISPR and Cas Gene Market is segmented into Kits and Enzymes, Libraries, Design Tool, Antibodies, and Other Products. The Kits and Enzymes segment dominated the market in 2024.
• By Services For Product and Service, the South and Central America CRISPR and Cas Gene Market is segmented into DNA synthesis, Cell Line Engineering, gRNA Design, and Microbial Gene Editing. The DNA synthesis segment dominated the market in 2024.
• By Application, the South and Central America CRISPR and Cas Gene Market is segmented into Biomedical and Agriculture. The Biomedical segment dominated the market in 2024.
• By Biomedical For Application, the South and Central America CRISPR and Cas Gene Market is segmented into Genome Engineering, Disease Models, Functional Genomics, Epigenetics, and Other Biomedicals. The Genome Engineering segment dominated the market in 2024.
• By End User, the South and Central America CRISPR and Cas Gene Market is segmented into Biotechnology and Pharmaceutical Companies, Academics and Government Research Institutes, and Contract Research Organizations (CRO) and CDMOs. The Biotechnology and Pharmaceutical Companies segment dominated the market in 2024.

South & Central America CRISPR and Cas Gene Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America CRISPR and Cas Gene Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South and Central America CRISPR and Cas Gene Market Outlook

The CRISPR-Cas9 system, pioneered by Jennifer Doudna and Emmanuelle Charpentier, has evolved rapidly since 2012, transforming gene editing from a lab tool to a therapeutic powerhouse. Recent innovations focus on precision, reducing off-target effects, and expanding applications in medicine, agriculture, and beyond. Key players such as CRISPR Therapeutics, Beam Therapeutics, and Pairwise Plants are driving this revolution in the CRISPR and Cas gene market.

A landmark advancement is base editing, which enables single-nucleotide changes without double-strand breaks, minimizing genomic instability. Beam Therapeutics' BEAM-101, a base editor targeting SCD, dosed its first patient in January 2024, reactivating fetal hemoglobin via an A-to-G transition in the BCL11A gene. This move builds on CRISPR Therapeutics' Casgevy (exa-cel), approved by the FDA in December 2023 for SCD and beta-thalassemia, with over 90 patients initiating treatment by May 2025 and 65 authorized centers worldwide. It edits patients' hematopoietic stem cells to boost fetal hemoglobin production, offering durable remission in 94% of trial participants after one year, per FDA data.

Prime editing, introduced by David Liu's team, offers "search-and-replace" edits without donor DNA. In 2024, it enhanced rice resistance to bacterial blight by modifying Xa13 and Xa25 genes, boosting yields by up to 20% in field tests. Mammoth Biosciences' NanoCas system, unveiled in January 2025, enables extrahepatic editing with a single AAV vector, expanding in vivo applications.

Cas13 innovations target RNA for transient editing, making them ideal for viral therapies. In oncology, CRISPR-modified T cells knocked out immune rejection genes, achieving complete B-cell depletion in trials for autoimmune diseases such as SLE. These breakthroughs, led by firms such as Editas Medicine and Intellia Therapeutics, herald a future of curative therapies. CRISPR-Cas systems are today's engine of precision genetic medicine and sustainable agriculture, poised to deliver transformative impact throughout this decade.

South and Central America CRISPR and Cas Gene Market Country Insights

By country, the South and Central America CRISPR and Cas Gene Market is segmented into Brazil, Argentina, and the Rest of South and Central America. Brazil held the largest share in 2024.

As per a study titled "Medical genetics workforce in Brazil: practitioners, services, and disease distribution," published in 2021, ~53,746 live births were with rare genetic diseases. Similarly, as per a study titled "The Brazilian Rare Genomes Project," published in May 2022, 13.2 million individuals were affected by rare diseases in Brazil, fostering the need for innovative therapies.

With over 112 health-related CRISPR publications between 2010 and 2021, Brazil accounts for nearly 60% of the region's output, focusing on experimental studies in cancer, neurological disorders, and sickle cell disease (SCD), which affects approximately 100,000 Brazilians and reduces life expectancy by 32 years. At the University of Sao Paulo (USP) and the Brazilian Agricultural Research Corporation (EMBRAPA), researchers have adapted CRISPR-Cas9 to edit fetal hemoglobin genes in SCD models, reactivating healthy hemoglobin production to alleviate vaso-occlusive crises, mirroring global trials such as CTX001 that achieved 100% symptom resolution in patients. Funding from the Sao Paulo Research Foundation (FAPESP) has supported over 20 CRISPR projects since 2013, including gene therapy for inborn errors of metabolism, with grants totaling millions of reais to foster clinical translation. Brazil holds 128 CRISPR-related patents, many disease-oriented for immunological and hematological therapies, filed through the Butantan Institute, which explores Cas9 knockouts for viral resistance in endemic diseases such as dengue.

The Ministry of Health's genetic screening programs leverage the potential of CRISPR for early intervention. University spin-offs and public-private collaborations are reducing healthcare costs for chronic diseases via curative therapies, as evidenced by preclinical successes in endocrine disorders. This move positions Brazil not just as a research hub but as a model for affordable gene editing in emerging economies.

South and Central America CRISPR and Cas Gene Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc, QIAGEN NV, Merck KGaA, GenScript Biotech Corporation, Horizon Discovery Group plc., Takara Bio Inc, CRISPR Therapeutics, Editas Medicine Inc, Integrated DNA Technologies Inc., and Synthego Holdings LLC.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South and Central America CRISPR and Cas Gene Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise